September 2014

Safety Related Changes

Adriamycin (doxorubicin hydrochloride) is now contraindicated for IV use in the following conditions: severe myocardial insufficiency, recent MI, severe liver impairment, presence of generalised infection and in persistent myelosuppression. Adriamycin for intravesical use is now contraindicated with haematuria.

Daonil (glibenclamide)  is now contraindicated in the treatment of diabetic ketoacidosis.

Telzir (fosamprenavir calcium)  is now contraindicated with quetiapine.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au